Crystalline forms of [3-(4- {2-butyl- 1 -[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine
US7884219B2 · kind B2 · utility
9Cited by
1References
19Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Mar 12, 2008 |
| Grant date | Feb 8, 2011 |
| Priority date | — |
| Expiry date | Nov 12, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to crystalline forms of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethylamine (“COMPOUND I”) useful in the treatment of RAGE mediated diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.